Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
4.110
+0.210 (5.38%)
At close: Mar 9, 2026, 4:00 PM EDT
3.990
-0.120 (-2.92%)
After-hours: Mar 9, 2026, 4:59 PM EDT
Voyager Therapeutics Revenue
In the year 2025, Voyager Therapeutics had annual revenue of $40.37M, down -49.53%. Voyager Therapeutics had revenue of $15.34M in the quarter ending December 31, 2025, with 144.28% growth.
Revenue (ttm)
$40.37M
Revenue Growth
-49.53%
P/S Ratio
5.66
Revenue / Employee
$234,733
Employees
172
Market Cap
228.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.37M | -39.63M | -49.53% |
| Dec 31, 2024 | 80.00M | -170.01M | -68.00% |
| Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
| Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
| Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| Protalix BioTherapeutics | 61.84M |
| Editas Medicine | 40.52M |
| Sol-Gel Technologies | 18.97M |
| MediWound | 16.96M |
| Cartesian Therapeutics | 2.80M |
| Humacyte | 1.57M |
VYGR News
- 2 hours ago - Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - GlobeNewsWire
- 6 days ago - Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript - Seeking Alpha
- 4 weeks ago - Voyager to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia - GlobeNewsWire
- 4 months ago - Voyager Reports Third Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 6 months ago - Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 7 months ago - Voyager Reports Second Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 8 months ago - Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewsWire